Abstract:Abstract Background: Tumor heterogeneity plays a crucial role in disease progression, metastasis and treatment response in lung adenocarcinoma (LUAD). Limited availability of multiple molecularly profiled samples from the same patients poses a challenge to validate models of tumor evolution using real-world data. We investigated genomic changes in a large cohort of patients with clinically directed DNA sequencing of multiple LUAD samples. Methods: We analyzed longitudinal genomic data from 524 patients with at least two LUAD samples sequenced with MSK-IMPACT- a targeted panel that identifies somatic mutations, copy number alterations and gene fusions in 341-505 genes. Our analysis of 1084 tumors (634 primaries [P] and 450 metastases [M]) included 189 matched P-P pairs, 99 M-M pairs and 271 P-M pairs. Pairs were required to share an identical somatic mutation to confirm relatedness. Additional criteria included: excision of primary tumor prior to excision of the metastasis in P-M pairs collected over 90 days apart and collection of M-M pairs from the same anatomic site. Intra-pulmonary metastases were removed from P-P pairs. Results: Tumor mutational burden was correlated in paired specimens from the same patient, irrespectively of P-P (R= 0.75, p<0.001; Spearman correlation), P-M (R=0.72, p<0.001) or M-M (R=0.6, p<0.001) status. Chromosomal instability, measured as the fraction of genome altered by copy number changes (FGA), was also correlated in P-P (R=0.69, p<0.001) and M-M (R=0.57, p<0.001) pairs, but tended to increase in metastases with respect to matched primaries (median 0.58 vs. 0.72, p<0.001; Wilcoxon test). In M-M pairs, changes in FGA differed by anatomic site. Liver pairs had the strongest correlation (n=17 pairs, R=0.86, p <0.01), whereas brain pairs had the weakest (n=35 pairs, R=0.085, p=0.71). Most somatic mutations were shared between paired samples (P-P: 639/1055, 60%, P-M: 1563/2877, 54%, M-M: 550/958, 57%), including those in LUAD drivers- TP53, KRAS, and EGFR. Conversely, most oncogenic copy number alterations - including CDKN2A deletions and MET amplifications - were private to one specimen (P-P: 183/276, 66%, P-M: 880/1148, 76%, M-M: 430/601, 71%), most often in the later sample (P-P: 113/183, 61%, P-M: 636/880, 72%, M-M: 212/430, 49%). Clinically targetable alterations (OncoKB Level 1) tended to be shared by tumor pairs from the same patient (93% shared vs. 6% private in P-P, p<0.01; 85% vs. 14% in P-M, p<0.01; 78% vs. 21% in M-M, p <0.01). Conclusions: In LUAD, metastatic specimens exhibit increased chromosomal instability in relation to their matched primaries. This translates into unique copy number alterations detected only in the metastasis. By contrast, driver mutations - which account for most of the clinically targetable alterations with currently approved FDA drugs - are more often shared between paired samples from the same patient. Citation Format: Brooke Mastrogiacomo, Elizabeth G. Dunne, Cameron N. Fick, John Nguyen, Jairam Hathwar, Manendra Lankadasari, Yuan Liu, Soo-Ryum Yang, Jason Chang, Walid K. Chatila, Nikolaus Schultz, David R. Jones, Francisco Sanchez-Vega. Longitudinal analyses of clinical sequencing data provide novel insights into the evolutionary dynamics of lung adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2556.

Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway

Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study

Characterizing Tumor Microenvironment and Risk Genes in Lung Adenocarcinoma through scRNA-seq and Bulk RNA-seq Data

Comprehensive Investigation of Mutational Features of Various Lung Adenocarcinoma Histological Subtypes among Chinese Patients.

Correlation Analysis Between Driver Gene Mutation and Clinicopathological Features in Lung Adenocarcinoma Based on Real-World Cumulative Clinical Data

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma

The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma

Targeted Sequencing Analysis of Predominant Histological Subtypes in Resected Stage I Invasive Lung Adenocarcinoma

Distinct gene mutation profiles among multiple and single primary lung adenocarcinoma

Genetic Alteration Profiling of Chinese Lung Adenocarcinoma and Its Effect on Targeted Therapy Efficacy

Systematic Identification of Cancer-Related Long Noncoding RNAs and Aberrant Alternative Splicing of Quintuple-Negative Lung Adenocarcinoma Through RNA-Seq

Abstract 5047: Identifying genomic features associated with pathologic lymph node metastasis in lung adenocarcinoma patients

Intratumor Heterogeneity in Localized Lung Adenocarcinomas Delineated by Multiregion Sequencing

Abstract 2556: Longitudinal analyses of clinical sequencing data provide novel insights into the evolutionary dynamics of lung adenocarcinoma

Non-small cell lung carcinomas with diffuse coexpression of TTF1 and p40: clinicopathological and genomic features of 14 rare biphenotypic tumours

Targeted Sequencing Reveals Distinct Pathogenic Variants in Chinese Patients with Lung Adenocarcinoma Brain Metastases.

Identifying potential therapeutic targets in lung adenocarcinoma: a multi-omics approach integrating bulk and single-cell RNA sequencing with Mendelian randomization

Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival

Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities

A cellular and spatial atlas of -associated tissue remodeling in lung adenocarcinoma